reports
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Office...
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory and reimbursement supportWill assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company’s Consulting Chief Medical Officer. In this part-time role, he will support a range of strategic and ...
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA)MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-CodeUp to 20% of patients will have detectable DSA within the first five years post kidney transplant, representing greater than 10,000 patients per year in the US.1 From time of onset of dnDSA, 24% of patients will lose their allograft withi...
Beyond Air to Participate in the Lytham Partners 2025 Investor Healthc...
Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 GARDEN CITY, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
TXRH TEXAS ROADHOUSE INC.
TPH TRI POINTE HOMES INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
LGIH LGI HOMES INC.
LEN LENNAR CORPORATION CLASS A
INTC INTEL CORPORATION
HMST HOMESTREET INC.
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EWBC EAST WEST BANCORP INC.
CCS CENTURY COMMUNITIES INC.
AXTI AXT INC.
INOD INNODATA
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ROKU ROKU INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
LSEA LANDSEA HOMES CORP (A)
STX SEAGATE TECHNOLOGY HLDGS PLC
TTD THE TRADE DESK
SWI INC.
GFS SOLARWINDS CORP
ALCC GLOBALFOUNDRIES INC
LAC. ALTC ACQUISITION CORP
OS LITHIUM AMERICAS CORP NEW
ONESTREAM INC
- Brian Violino
- Jay McCanless
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetin...
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings January 13-16, 2025, San Francisco, CA IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43ʳᵈ Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13-16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors. Investors wishing to schedule a ...
Oncocyte Corporation: 1 director
A director at Oncocyte Corporation bought 20,000 shares at 2.290USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Landsea Homes Corporation Announces Pricing of Public Secondary Offeri...
Landsea Homes Corporation Announces Pricing of Public Secondary Offering DALLAS, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”), a publicly traded residential homebuilder, today announced the pricing of an underwritten public offering of 6,086,957 shares of its common stock being sold by selling stockholders of the Company, Landsea Holdings Corporation and Ever Fast Holdings Limited, at a public offering price of $10.25 per share, for total gross proceeds of approximately $62.4 million to the selling stockholders, before deduc...
Landsea Homes Corporation Announces Proposed Secondary Offering of Com...
Landsea Homes Corporation Announces Proposed Secondary Offering of Common Stock DALLAS, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”), a publicly traded residential homebuilder, today announced the commencement of an underwritten public offering of 5,043,480 shares of its common stock to be offered by selling stockholders of the Company (collectively, the “Offering”). The selling stockholders also expect to grant the underwriters a 30-day option to purchase up to an additional 756,520 shares of common stock. The Company is no...
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in N...
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. In a in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number instability (CNI) is a scientifically well-kn...
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months...
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection. Study published in IRVINE, Calif., Dec. 02...
Beyond Air Receives CE Mark in Europe for the LungFit® PH System
Beyond Air Receives CE Mark in Europe for the LungFit® PH System Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery A $1 million milestone payment is triggered from Asia-Pacific partner, Getz Healthcare GARDEN CITY, N.Y., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the ...
NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Adv...
NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board Professor Kornberg will assist in accelerating the development of treatments for Autism Spectrum Disorder and potentially other neurological disorders DUBLIN and GARDEN CITY, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, and a subsidiary of Beyond Air (NASDAQ: XAIR), is proud to announce the appointment of Professor Roger D. Kornberg, to it...
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare ...
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference GARDEN CITY, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of Nitric Oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024 in New York. Fi...
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Trans...
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phaseFDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today published the following letter to shareholders in conjunction with its third ...
Team, Inc. Reports Third Quarter 2024 Results
Team, Inc. Reports Third Quarter 2024 Results SUGAR LAND, Texas, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering clients access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today reported its financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights: Generated revenue of $210.8 million, up 2% over third quarter 2023.Maintained gross margin of 25.4%.Improved operating in...
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and P...
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group Conference call scheduled for 4:30 p.m. ET today, November 11t...
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-...
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth inhibition rate in MAT B III tumor bearing rats compared to anti-rPD-L1 alone - LV UNO compares favorably to HV UNO administration in reducing tumor volumes in combination with anti-mPD-1 in CT26 BALB/c mice - Increased nitro-tyrosine staining in LV UNO treated tumors indicates an improved dis...
Landsea Homes to Present at the 16th Annual Southwest IDEAS Investor C...
Landsea Homes to Present at the 16th Annual Southwest IDEAS Investor Conference in Dallas, Texas on Thursday, November 21 DALLAS, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Landsea Homes Corporation (NASDAQ: LSEA) today announced that the company will present at the Southwest IDEAS Investor Conference on Thursday, November 21, 2024 at The Statler in Dallas, TX. Company’s presentation is scheduled to begin at 11:30 AM local time (12:30 ET). The presentation will be webcast and can be accessed through the conference host’s main website: /southwest and in the investor relations section of the company...
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and highlights. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.